Key result
Commonly used activated clotting time (ACT) systems differ in reagents, detection methods, and calibration, leading to substantial heterogeneity in electrophysiology practice.
Highlights the potential clinical impact of platform- and cartridge-dependent variability in activated clotting time (ACT) measurements during left-sided ablation procedures, suggesting that a uniform target of >300 seconds may not be universally applicable.
Activated clotting time (ACT) is routinely used to guide unfractionated heparin administration during left-sided electrophysiology procedures, with current consensus recommendations targeting an ACT >300 seconds.1 However, commonly used ACT systems differ in reagents, detection methods, and calibration, while recommendations generally do not specify the measurement platform. Our previous international survey and systematic review demonstrated substantial heterogeneity in ACT platforms and anticoagulation strategies used in electrophysiology practice.
No takes yet. Share an insight, caveat, or question.
Spahiu et al. (2026) conducted an editorial in Left-sided electrophysiology procedures. Activated clotting time (ACT) platforms was evaluated. Commonly used activated clotting time (ACT) systems differ in reagents, detection methods, and calibration, leading to substantial heterogeneity in electrophysiology practice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: